ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 1797

Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2380

Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2415

Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2405

Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1775

Childhood-onset Sjögren Disease Has an Altered Peripheral Blood Immune Landscape Compared to Adult-onset Disease Characterized by Activated CD4+ T-cells Which Could Drive B-cell Dysregulation

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2389

Choroidal Thickness in Active Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2317

Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1763

Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1846

Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2067

Clinical and Laboratory Characterization of Overlap Connective Tissue Disease in Patients with Idiopathic Inflammatory Myopathies: Results from the MYOTReCSZ Cohort

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2072

Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2419

Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2299

Clinical and Serological Characteristics of Sjögren’s Disease-related Lymphocytic Interstitial Pneumonia: A Large Multicenter Study

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2497

Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2511

Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].